

Antihemophilic Factor (Recombinant) Market, Global Outlook and Forecast 2022-2028

<https://marketpublishers.com/r/ABC2C6F66FF3EN.html>

Date: February 2022

Pages: 66

Price: US\$ 3,250.00 (Single User License)

ID: ABC2C6F66FF3EN

Abstracts

Antihemophilic factor is a naturally occurring protein in the blood that helps blood to clot.

This report contains market size and forecasts of Antihemophilic Factor (Recombinant) in Global, including the following market information:

Global Antihemophilic Factor (Recombinant) Market Revenue, 2017-2022, 2023-2028, (\$ millions)

Global top five companies in 2021 (%)

The global Antihemophilic Factor (Recombinant) market was valued at million in 2021 and is projected to reach US\$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at \$ Million in 2021, While China is Forecast to Reach \$ Million by 2028.

250IU Segment to Reach \$ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Antihemophilic Factor (Recombinant) include Takeda, Bayer, CSL, Pfizer, Biogen, Octapharma and NovoNordisk, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Antihemophilic Factor (Recombinant) companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers,

challenges, obstacles, and potential risks.

Total Market by Segment:

Global Antihemophilic Factor (Recombinant) Market, by Type, 2017-2022, 2023-2028 (\$ millions)

Global Antihemophilic Factor (Recombinant) Market Segment Percentages, by Type, 2021 (%)

250IU

500IU

1000IU

1500IU

2000IU

Global Antihemophilic Factor (Recombinant) Market, by Application, 2017-2022, 2023-2028 (\$ millions)

Global Antihemophilic Factor (Recombinant) Market Segment Percentages, by Application, 2021 (%)

Hospital

Clinic

Global Antihemophilic Factor (Recombinant) Market, By Region and Country, 2017-2022, 2023-2028 (\$ Millions)

Global Antihemophilic Factor (Recombinant) Market Segment Percentages, By Region and Country, 2021 (%)

North America

US

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Nordic Countries

Benelux

Rest of Europe

Asia

China

Japan

South Korea

Southeast Asia

India

Rest of Asia

South America

Brazil

Argentina

Rest of South America

Middle East & Africa

Turkey

Israel

Saudi Arabia

UAE

Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

Key companies Antihemophilic Factor (Recombinant) revenues in global market, 2017-2022 (estimated), (\$ millions)

Key companies Antihemophilic Factor (Recombinant) revenues share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

Takeda

Bayer

CSL

Pfizer

Biogen

Octapharma

NovoNordisk

Contents

1 INTRODUCTION TO RESEARCH & ANALYSIS REPORTS

- 1.1 Antihemophilic Factor (Recombinant) Market Definition
- 1.2 Market Segments
 - 1.2.1 Market by Type
 - 1.2.2 Market by Application
- 1.3 Global Antihemophilic Factor (Recombinant) Market Overview
- 1.4 Features & Benefits of This Report
- 1.5 Methodology & Sources of Information
 - 1.5.1 Research Methodology
 - 1.5.2 Research Process
 - 1.5.3 Base Year
 - 1.5.4 Report Assumptions & Caveats

2 GLOBAL ANTIHEMOPHILIC FACTOR (RECOMBINANT) OVERALL MARKET SIZE

- 2.1 Global Antihemophilic Factor (Recombinant) Market Size: 2021 VS 2028
- 2.2 Global Antihemophilic Factor (Recombinant) Market Size, Prospects & Forecasts: 2017-2028
- 2.3 Key Market Trends, Opportunity, Drivers and Restraints
 - 2.3.1 Market Opportunities & Trends
 - 2.3.2 Market Drivers
 - 2.3.3 Market Restraints

3 COMPANY LANDSCAPE

- 3.1 Top Antihemophilic Factor (Recombinant) Players in Global Market
- 3.2 Top Global Antihemophilic Factor (Recombinant) Companies Ranked by Revenue
- 3.3 Global Antihemophilic Factor (Recombinant) Revenue by Companies
- 3.4 Top 3 and Top 5 Antihemophilic Factor (Recombinant) Companies in Global Market, by Revenue in 2021
- 3.5 Global Companies Antihemophilic Factor (Recombinant) Product Type
- 3.6 Tier 1, Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Players in Global Market
 - 3.6.1 List of Global Tier 1 Antihemophilic Factor (Recombinant) Companies
 - 3.6.2 List of Global Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Companies

4 MARKET SIGHTS BY PRODUCT

4.1 Overview

4.1.1 by Type - Global Antihemophilic Factor (Recombinant) Market Size Markets, 2021 & 2028

4.1.2 250IU

4.1.3 500IU

4.1.4 1000IU

4.1.5 1500IU

4.1.6 2000IU

4.2 By Type - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts

4.2.1 By Type - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022

4.2.2 By Type - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028

4.2.3 By Type - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028

5 SIGHTS BY APPLICATION

5.1 Overview

5.1.1 By Application - Global Antihemophilic Factor (Recombinant) Market Size, 2021 & 2028

5.1.2 Hospital

5.1.3 Clinic

5.2 By Application - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts

5.2.1 By Application - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022

5.2.2 By Application - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028

5.2.3 By Application - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028

6 SIGHTS BY REGION

6.1 By Region - Global Antihemophilic Factor (Recombinant) Market Size, 2021 & 2028

6.2 By Region - Global Antihemophilic Factor (Recombinant) Revenue & Forecasts

6.2.1 By Region - Global Antihemophilic Factor (Recombinant) Revenue, 2017-2022

6.2.2 By Region - Global Antihemophilic Factor (Recombinant) Revenue, 2023-2028

6.2.3 By Region - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028

6.3 North America

6.3.1 By Country - North America Antihemophilic Factor (Recombinant) Revenue, 2017-2028

6.3.2 US Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.3.3 Canada Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.3.4 Mexico Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4 Europe

6.4.1 By Country - Europe Antihemophilic Factor (Recombinant) Revenue, 2017-2028

6.4.2 Germany Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4.3 France Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4.4 U.K. Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4.5 Italy Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4.6 Russia Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4.7 Nordic Countries Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.4.8 Benelux Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.5 Asia

6.5.1 By Region - Asia Antihemophilic Factor (Recombinant) Revenue, 2017-2028

6.5.2 China Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.5.3 Japan Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.5.4 South Korea Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.5.5 Southeast Asia Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.5.6 India Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.6 South America

6.6.1 By Country - South America Antihemophilic Factor (Recombinant) Revenue, 2017-2028

6.6.2 Brazil Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.6.3 Argentina Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.7 Middle East & Africa

6.7.1 By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, 2017-2028

6.7.2 Turkey Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.7.3 Israel Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.7.4 Saudi Arabia Antihemophilic Factor (Recombinant) Market Size, 2017-2028

6.7.5 UAE Antihemophilic Factor (Recombinant) Market Size, 2017-2028

7 PLAYERS PROFILES

7.1 Takeda

7.1.1 Takeda Corporate Summary

- 7.1.2 Takeda Business Overview
- 7.1.3 Takeda Antihemophilic Factor (Recombinant) Major Product Offerings
- 7.1.4 Takeda Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
- 7.1.5 Takeda Key News
- 7.2 Bayer
 - 7.2.1 Bayer Corporate Summary
 - 7.2.2 Bayer Business Overview
 - 7.2.3 Bayer Antihemophilic Factor (Recombinant) Major Product Offerings
 - 7.2.4 Bayer Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
 - 7.2.5 Bayer Key News
- 7.3 CSL
 - 7.3.1 CSL Corporate Summary
 - 7.3.2 CSL Business Overview
 - 7.3.3 CSL Antihemophilic Factor (Recombinant) Major Product Offerings
 - 7.3.4 CSL Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
 - 7.3.5 CSL Key News
- 7.4 Pfizer
 - 7.4.1 Pfizer Corporate Summary
 - 7.4.2 Pfizer Business Overview
 - 7.4.3 Pfizer Antihemophilic Factor (Recombinant) Major Product Offerings
 - 7.4.4 Pfizer Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
 - 7.4.5 Pfizer Key News
- 7.5 Biogen
 - 7.5.1 Biogen Corporate Summary
 - 7.5.2 Biogen Business Overview
 - 7.5.3 Biogen Antihemophilic Factor (Recombinant) Major Product Offerings
 - 7.5.4 Biogen Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)
 - 7.5.5 Biogen Key News
- 7.6 Octapharma
 - 7.6.1 Octapharma Corporate Summary
 - 7.6.2 Octapharma Business Overview
 - 7.6.3 Octapharma Antihemophilic Factor (Recombinant) Major Product Offerings
 - 7.6.4 Octapharma Antihemophilic Factor (Recombinant) Revenue in Global Market (2017-2022)

7.6.5 Octapharma Key News

7.7 NovoNordisk

7.7.1 NovoNordisk Corporate Summary

7.7.2 NovoNordisk Business Overview

7.7.3 NovoNordisk Antihemophilic Factor (Recombinant) Major Product Offerings

7.7.4 NovoNordisk Antihemophilic Factor (Recombinant) Revenue in Global Market
(2017-2022)

7.7.5 NovoNordisk Key News

8 CONCLUSION

9 APPENDIX

9.1 Note

9.2 Examples of Clients

9.3 Disclaimer

List Of Tables

LIST OF TABLES

- Table 1. Antihemophilic Factor (Recombinant) Market Opportunities & Trends in Global Market
- Table 2. Antihemophilic Factor (Recombinant) Market Drivers in Global Market
- Table 3. Antihemophilic Factor (Recombinant) Market Restraints in Global Market
- Table 4. Key Players of Antihemophilic Factor (Recombinant) in Global Market
- Table 5. Top Antihemophilic Factor (Recombinant) Players in Global Market, Ranking by Revenue (2021)
- Table 6. Global Antihemophilic Factor (Recombinant) Revenue by Companies, (US\$, Mn), 2017-2022
- Table 7. Global Antihemophilic Factor (Recombinant) Revenue Share by Companies, 2017-2022
- Table 8. Global Companies Antihemophilic Factor (Recombinant) Product Type
- Table 9. List of Global Tier 1 Antihemophilic Factor (Recombinant) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 10. List of Global Tier 2 and Tier 3 Antihemophilic Factor (Recombinant) Companies, Revenue (US\$, Mn) in 2021 and Market Share
- Table 11. By Type – Global Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2021 & 2028
- Table 12. By Type - Antihemophilic Factor (Recombinant) Revenue in Global (US\$, Mn), 2017-2022
- Table 13. By Type - Antihemophilic Factor (Recombinant) Revenue in Global (US\$, Mn), 2023-2028
- Table 14. By Application – Global Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2021 & 2028
- Table 15. By Application - Antihemophilic Factor (Recombinant) Revenue in Global (US\$, Mn), 2017-2022
- Table 16. By Application - Antihemophilic Factor (Recombinant) Revenue in Global (US\$, Mn), 2023-2028
- Table 17. By Region – Global Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2021 & 2028
- Table 18. By Region - Global Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), 2017-2022
- Table 19. By Region - Global Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), 2023-2028
- Table 20. By Country - North America Antihemophilic Factor (Recombinant) Revenue,

(US\$, Mn), 2017-2022

Table 21. By Country - North America Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2023-2028

Table 22. By Country - Europe Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2022

Table 23. By Country - Europe Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2023-2028

Table 24. By Region - Asia Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2022

Table 25. By Region - Asia Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2023-2028

Table 26. By Country - South America Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2022

Table 27. By Country - South America Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2023-2028

Table 28. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2022

Table 29. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2023-2028

Table 30. Takeda Corporate Summary

Table 31. Takeda Antihemophilic Factor (Recombinant) Product Offerings

Table 32. Takeda Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), (2017-2022)

Table 33. Bayer Corporate Summary

Table 34. Bayer Antihemophilic Factor (Recombinant) Product Offerings

Table 35. Bayer Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), (2017-2022)

Table 36. CSL Corporate Summary

Table 37. CSL Antihemophilic Factor (Recombinant) Product Offerings

Table 38. CSL Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), (2017-2022)

Table 39. Pfizer Corporate Summary

Table 40. Pfizer Antihemophilic Factor (Recombinant) Product Offerings

Table 41. Pfizer Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), (2017-2022)

Table 42. Biogen Corporate Summary

Table 43. Biogen Antihemophilic Factor (Recombinant) Product Offerings

Table 44. Biogen Antihemophilic Factor (Recombinant) Revenue (US\$, Mn), (2017-2022)

Table 45. Octapharma Corporate Summary

Table 46. Octapharma Antihemophilic Factor (Recombinant) Product Offerings

Table 47. Octapharma Antihemophilic Factor (Recombinant) Revenue (US\$, Mn),

(2017-2022)

Table 48. NovoNordisk Corporate Summary

Table 49. NovoNordisk Antihemophilic Factor (Recombinant) Product Offerings

Table 50. NovoNordisk Antihemophilic Factor (Recombinant) Revenue (US\$, Mn),
(2017-2022)

List Of Figures

LIST OF FIGURES

- Figure 1. Antihemophilic Factor (Recombinant) Segment by Type in 2021
- Figure 2. Antihemophilic Factor (Recombinant) Segment by Application in 2021
- Figure 3. Global Antihemophilic Factor (Recombinant) Market Overview: 2021
- Figure 4. Key Caveats
- Figure 5. Global Antihemophilic Factor (Recombinant) Market Size: 2021 VS 2028 (US\$, Mn)
- Figure 6. Global Antihemophilic Factor (Recombinant) Revenue, 2017-2028 (US\$, Mn)
- Figure 7. The Top 3 and 5 Players Market Share by Antihemophilic Factor (Recombinant) Revenue in 2021
- Figure 8. By Type - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
- Figure 9. By Application - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
- Figure 10. By Region - Global Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
- Figure 11. By Country - North America Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
- Figure 12. US Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 13. Canada Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 14. Mexico Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 15. By Country - Europe Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028
- Figure 16. Germany Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 17. France Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 18. U.K. Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 19. Italy Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 20. Russia Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 21. Nordic Countries Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028
- Figure 22. Benelux Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn),

2017-2028

Figure 23. By Region - Asia Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028

Figure 24. China Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 25. Japan Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 26. South Korea Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 27. Southeast Asia Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 28. India Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 29. By Country - South America Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028

Figure 30. Brazil Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 31. Argentina Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 32. By Country - Middle East & Africa Antihemophilic Factor (Recombinant) Revenue Market Share, 2017-2028

Figure 33. Turkey Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 34. Israel Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 35. Saudi Arabia Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 36. UAE Antihemophilic Factor (Recombinant) Revenue, (US\$, Mn), 2017-2028

Figure 37. Takeda Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 38. Bayer Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 39. CSL Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 40. Pfizer Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 41. Biogen Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 42. Octapharma Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

Figure 43. NovoNordisk Antihemophilic Factor (Recombinant) Revenue Year Over Year Growth (US\$, Mn) & (2017-2022)

I would like to order

Product name: Antihemophilic Factor (Recombinant) Market, Global Outlook and Forecast 2022-2028

Product link: <https://marketpublishers.com/r/ABC2C6F66FF3EN.html>

Price: US\$ 3,250.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ABC2C6F66FF3EN.html>